Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
調査の概要
詳細な説明
Until very recently, additional therapies in pancreatic cancer have targeted either the vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF) pathways, a strategy which has shown variable clinical efficacy. This inconsistency is not surprising, given the knowledge that tumors have a certain level of signal redundancy which may limit the effectiveness of any one single-targeted therapy. The dual blockade of the EGF and VEGF pathways takes aim at two of the most active cascades in tumorigenesis. Preliminarily, a phase II study done in pancreatic cancer with gemcitabine, bevacizumab and erlotinib or cetuximab has shown promising results and will most likely proceed to phase III study for definitive efficacy assessment (Kindler et al, 2006).
In this study, targeted blockade is carried one step further with the inhibition of the signaling cascade downstream of receptor tyrosine kinases at the level of raf. Given the fact that the majority of pancreatic tumors display constitutive activation of the Ras/Raf/MEK/ERK pathway, it is hoped that the addition of sorafenib to gemcitabine and erlotinib will obtain a more complete blockade of the signal transduction cascade responsible for pancreatic tumor growth and progression.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Palm Springs、California、アメリカ、92262
- Desert Regional Medical Center
-
-
New York
-
New York、New York、アメリカ、10016
- Bellevue Hospital
-
New York、New York、アメリカ、10016
- New York University Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically or cytologically confirmed pancreatic adenocarcinoma not amenable to curative treatment with surgery. Patients with locally advanced disease must have disease that extends outside the boundaries of a standard radiation port.
- Measurable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST). This requires at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. Pleural effusions and ascites are not considered measurable lesions.
- No prior cytotoxic chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed, however at least 6 months must have elapsed from administration of the last dose of chemotherapy or radiotherapy.
- No prior therapy with a VEGF, EGFR, or multi-targeted kinase inhibitor.
- Age >18 years.
- Life expectancy of greater than 3 months.
- Eastern Cooperative Oncology Group performance status 0-1.
Normal organ and marrow function as defined below:
- White blood cells (WBC) >3,000/µl
- Absolute neutrophil count >1,500/µl
- Platelets >100,000/µl
- Total bilirubin ≤ 2.5 x institutional upper limit of normal (ULN)
Transaminases(SGOT/ SGPT)
- without liver mets ≤ 2.5 x institutional ULN
- with liver mets ≤ 5 x institutional ULN
International Normalized Ratio (INR)
- patients not on warfarin ≤ 1.5
- patients on warfarin ≤ 3
- Renal Function: Serum creatinine ≤ 1.5 xULN
- Proteinuria: Urine protein <1+, or 24hr urine protein <500 mg
- At least 30 days since receiving any investigational drug.
- Patients who received prior radiation therapy must have a site of measurable disease that is not located within the prior radiation port.
Patients who are on warfarin anticoagulation are allowed to participate as long as they fit the following 3 criteria:
- They are therapeutic on a stable warfarin dose
- Their INR target range is no greater than 3
- They are monitored with regular INR testing
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.
- Women of childbearing potential and men must agree to use adequate contraception (barrier method birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of study drugs.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- No prior treatment with bevacizumab, cetuximab, or erlotinib. Prior gemcitabine in the adjuvant setting completed more than six months previously will be allowed.
- No other investigational agents.
- No central nervous system (CNS) disease, including primary brain tumors, brain metastasis, or history of a cerebro-vascular accident (CVA) or transient ischemic attack (TIA) within 6 months of starting therapy.
- No allergic reactions to compounds similar to erlotinib or sorafenib.
- Because an increased risk of bleeding may occur following sorafenib administration, no patients will be allowed with a history of bleeding diathesis or coagulopathy. No grade > 2 pulmonary hemorrhage or > grade 3 other hemorrhage within 28 days of beginning therapy.
- No recent invasive procedures defined as follows: Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 of therapy
No Patients with clinically significant cardiovascular disease, defined as:
- Uncontrolled hypertension
- Myocardial infarction < 6 months prior to registration and new onset angina within 3 months (controlled stable angina acceptable)
- New York heart association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris
- Grade II or greater peripheral vascular disease
- No serious or non-healing wound, ulcer, or bone fracture.
- No active infection requiring parental antibiotics.
- No currently active second malignancy other than non-melanoma skin cancer or carcinoma in-situ of the cervix.
- If a patient is on full-dose anticoagulants (warfarin or low molecular weight heparins are allowed), the following criteria should be met for enrollment: they must have a therapeutic INR, no greater than 3, on a stable dose of warfarin.
- No use of thrombolytic agents within 1 month of study initiation.
- No gastrointestinal tract disease resulting in an inability to take oral medication or prior surgical procedures affecting absorption. This may include patients with or without requirements for IV alimentation.
- No women who are pregnant (positive pregnancy test) or nursing. Fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 3 months after the completion of antibody therapy.
- Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, no HIV-positive patients, including those receiving combination anti-retroviral therapy, are allowed on the study.
- Any condition that impairs patient's ability to swallow whole pills
- Any malabsorption problem
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Combination GES
Combination of Gemcitabine, Erlotinib, and Sorafenib
|
1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle.
In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
他の名前:
150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle.
In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
他の名前:
400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle.
In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
4-month Progression Free Survival (PFS) Rate
時間枠:4 months
|
The PFS rate at 4 months is defined as the percentage of patients whose disease is progression free at 4 months from the start of treatment.
Disease progression is evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al, 2000).
Radiological measurements to determine progression is performed every 2 cycles.
|
4 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Objective Response Rate
時間枠:up to 1 year
|
The response rate is the percentage of the patients who have a complete response or partial response based on RECIST from the start of the treatment.
The response is evaluated every 2 cycles by radiologic methods (e.g., computer tomography (CT)).
|
up to 1 year
|
Median Overall Survival (mOS)
時間枠:up to 2 years
|
Median overall survival is defined as the time when 50% of the patients are alive from the start of the treatment.
|
up to 2 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Deirdre Cohen, MD、NYU School of Medicine
出版物と役立つリンク
一般刊行物
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.
- Kindler HL, K. A. Bylow, H. S. Hochster, G. Friberg, K. Micetich, G. Locker, M. Kozloff, M. Moore, W. Sun, E. E. Vokes, and University Of Chicago Phase II Consortium. A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients with advanced pancreatic cancer: A preliminary analysis. J. Clin. Oncol (Meeting Abstracts) June 2006, vol. 24 no. 18_suppl 4040
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
膵臓癌の臨床試験
-
Washington University School of MedicineUniversity of Oklahoma Medical Center; Northwestern University Chicago Illinois; Saint Luke's...完了
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ